Scarica l'app Stockscreener
5.375
1.99%
0.105
Precedente Chiudi:
$5.27
Aprire:
$5.1
Volume 24 ore:
66,371
Relative Volume:
0.13
Capitalizzazione di mercato:
$9.26M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+16.09%
1M Prestazione:
+70.63%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.10
$5.41
Intervallo di 1 settimana:
$4.25
$5.49
Portata 52W:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Nome
Neuphoria Therapeutics Inc
Settore
Industria
Telefono
61 8 8150 7400
Indirizzo
200 GREENHILL ROAD, EASTWOOD SA
Confronta NEUP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
5.40 | 9.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.44 | 118.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.31 | 74.34B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
643.11 | 38.83B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.12 | 32.36B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.42 | 29.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Reiterato | Maxim Group | Buy |
| 2022-01-10 | Iniziato | Berenberg | Buy |
| 2022-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Iniziato | Evercore ISI | Outperform |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Neuphoria Therapeutics Inc Borsa (NEUP) Ultime notizie
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Neuphoria Therapeutics Inc.NEUPStock Price Today - Zacks Investment Research
We're Keeping An Eye On Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Rate - Yahoo Finance
Bionomics Strategic Shift with Neuphoria Redomiciliation - Yahoo Finance
Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation - MarketWatch
Big Moves in Biotech! Neuphoria's Bold Transformation Unveiled! - Jomfruland.net
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewswire
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Results of Scheme Meeting - The Manila Times
Bionomics Limited (BNOX) Quarterly 10-Q Report - Quartz
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewswire
Bionomics CEO believes company has ‘significant, unrealized value’ - Yahoo Finance
Apeiron entities sell Bionomics shares worth $82,526 - Investing.com
Bionomics Limited announces intention to re-domicile to the United States - StockTitan
Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder - Marketscreener.com
Bionomics to Present at Biotech Showcase™ 2024 - Marketscreener.com
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms - Marketscreener.com
BNOXBionomics Limited American Depository Shares Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics Inc Azioni (NEUP) Dati Finanziari
Non sono disponibili dati finanziari per Neuphoria Therapeutics Inc (NEUP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):